Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1990 2
1991 4
1992 1
1993 1
1995 2
1997 2
1999 2
2000 3
2002 2
2003 7
2004 8
2005 6
2006 3
2007 10
2008 2
2009 7
2010 14
2011 14
2012 27
2013 18
2014 21
2015 31
2016 46
2017 37
2018 41
2019 40
2020 42
Text availability
Article attribute
Article type
Publication date

Search Results

347 results
Results by year
Filters applied: . Clear all
Page 1
Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G. Mannucci C, et al. CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210. CNS Neurol Disord Drug Targets. 2017. PMID: 28412918 Review.
BACKGROUND: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. ...CONCLUSION: Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, …
BACKGROUND: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psycho …
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J, Cameron M. Rice J, et al. Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x. Curr Neurol Neurosci Rep. 2018. PMID: 29923025 Review.
RECENT FINDINGS: Two recent high-quality systematic reviews concluded that the only strong evidence for medical marijuana in neurological disorders was for reducing the symptoms of patient-reported spasticity and central pain in MS and that the only complementary and alter …
RECENT FINDINGS: Two recent high-quality systematic reviews concluded that the only strong evidence for medical marijuana in neurological di …
Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
Fasinu PS, Phillips S, ElSohly MA, Walker LA. Fasinu PS, et al. Pharmacotherapy. 2016 Jul;36(7):781-96. doi: 10.1002/phar.1780. Pharmacotherapy. 2016. PMID: 27285147 Review.
Sixteen states have legalized (or decriminalized possession of) products high in cannabidiol (CBD) and with restricted ∆(9) -tetrahydrocannabinol (∆(9) -THC) content. ...
Sixteen states have legalized (or decriminalized possession of) products high in cannabidiol (CBD) and with restricted ∆(9) -tetrahyd …
Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ(9)-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD.
Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, Vandelli MA, Forni F, Cannazza G. Palazzoli F, et al. J Pharm Biomed Anal. 2018 Feb 20;150:25-32. doi: 10.1016/j.jpba.2017.11.054. Epub 2017 Nov 28. J Pharm Biomed Anal. 2018. PMID: 29202305
The investigation of the possible conversion of cannabidiol (CBD) into Δ(9)-tetrahydrocannabinol (THC) in vivo after oral administration of CBD is reported herein since recent publications suggested a rapid conversion in simulated gastric fluid. ...A highly sensitive and s …
The investigation of the possible conversion of cannabidiol (CBD) into Δ(9)-tetrahydrocannabinol (THC) in vivo after oral administrat …
Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model.
Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA, ElSohly MA, Gurley BJ, Koturbash I. Ewing LE, et al. Molecules. 2019 Apr 30;24(9):1694. doi: 10.3390/molecules24091694. Molecules. 2019. PMID: 31052254 Free PMC article.
The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F(1) mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days (sub-acute …
The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F(1) mice. Animals were gavaged wit …
Phytochemistry of Cannabis sativa L.
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. ElSohly MA, et al. Prog Chem Org Nat Prod. 2017;103:1-36. doi: 10.1007/978-3-319-45541-9_1. Prog Chem Org Nat Prod. 2017. PMID: 28120229 Review.
Besides Δ(9)-THC, there are also non-psychoactive cannabinoids with several medicinal functions, such as cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG), along with other non-cannabinoid constituents belonging to diverse classes of natural products. ...
Besides Δ(9)-THC, there are also non-psychoactive cannabinoids with several medicinal functions, such as cannabidiol (CBD), cannabich …
Cannabidiol Regulates the Expression of Keratinocyte Proteins Involved in the Inflammation Process through Transcriptional Regulation.
Jastrząb A, Gęgotek A, Skrzydlewska E. Jastrząb A, et al. Cells. 2019 Aug 3;8(8):827. doi: 10.3390/cells8080827. Cells. 2019. PMID: 31382646 Free PMC article.
Cannabidiol (CBD), a natural phytocannabinoid without psychoactive effect, is a well-known anti-inflammatory and antioxidant compound. ...Furthermore, despite decreased glutathione peroxidase and reductase activities, CBD prevents lipid peroxidation, which was observed as …
Cannabidiol (CBD), a natural phytocannabinoid without psychoactive effect, is a well-known anti-inflammatory and antioxidant compound …
Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, Δ(9)-Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues.
Piscitelli F, Pagano E, Lauritano A, Izzo AA, Di Marzo V. Piscitelli F, et al. Anal Chem. 2017 Apr 18;89(8):4749-4755. doi: 10.1021/acs.analchem.7b01094. Epub 2017 Apr 3. Anal Chem. 2017. PMID: 28343385
., Δ(9)-tetrahydrocannabinol (Δ(9)-THC), led to the identification of at least 100 additional phytocannabinoids, including cannabidiol (CBD), cannabidivarin (CBDV), Δ(9)-tetrahydrocannabivarin (Δ(9)-THCV), and cannabigerol (CBG). ...The aim of this study was to set up a ra …
., Δ(9)-tetrahydrocannabinol (Δ(9)-THC), led to the identification of at least 100 additional phytocannabinoids, including cannabidiol …
A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.
Giacoppo S, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E. Giacoppo S, et al. Daru. 2015 Oct 21;23:48. doi: 10.1186/s40199-015-0131-8. Daru. 2015. PMID: 26489494 Free PMC article.
BACKGROUND: The present study was designed to investigate the efficacy of a new formulation of alone, purified cannabidiol (CBD) (>98 %), the main non-psychotropic cannabinoid of Cannabis sativa, as a topical treatment in an experimental model of autoimmune encephalomye …
BACKGROUND: The present study was designed to investigate the efficacy of a new formulation of alone, purified cannabidiol (CBD) (&gt …
Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Al-Ghezi ZZ, Miranda K, Nagarkatti M, Nagarkatti PS. Al-Ghezi ZZ, et al. Front Immunol. 2019 Aug 21;10:1921. doi: 10.3389/fimmu.2019.01921. eCollection 2019. Front Immunol. 2019. PMID: 31497013 Free PMC article.
Multiple sclerosis (MS) is a chronic and disabling disorder of the central nervous system (CNS) characterized by neuroinflammation leading to demyelination. Recently a combination of Δ9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) extracted from Cannabis has bee …
Multiple sclerosis (MS) is a chronic and disabling disorder of the central nervous system (CNS) characterized by neuroinflammation le …
347 results
Jump to page
Feedback